Gilead’s Livdelzi® (Seladelpar) Delivers Statistically Significant Composite ALP Normalization in Phase 3 IDEAL Trial in Primary Biliary Cholangitis (PBC)

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/28/2026

1. SPY
2. AKAM
3. COST
4. META
5. NVDA
6. ZS
7. PRME
8. AWK
9. DRI
10. USO

Go back to Gilead’s Livdelzi® (Seladelpar) Delivers Statistically Significant Composite ALP Normalization in Phase 3 IDEAL Trial in Primary Biliary Cholangitis (PBC)
Gilead Sciences (NASDAQ: GILD) Delayed: 150.93 --0 (-0%)
Previous Close $150.93    52 Week High $108.63 
Open $150.93    52 Week Low $71.39 
Day High $150.93    P/E 83.39 
Day Low $150.93    EPS $1.81 
Volume 2,706